The EPO published patent application EP3675832A1 titled 'Fast Self Dispersible Dosage Forms of Deferasirox' on March 25, 2026. The patent application covers pharmaceutical compositions of deferasirox (A61K 31/4196) in self-dispersing dosage form (A61K 9/46, A61K 9/20, A61K 9/00) with enhanced dissolution characteristics. Designated states include all 34 EPC contracting states covering EU member states, EFTA states, and the UK.

This document is a routine patent publication notice with no compliance requirements. Pharmaceutical manufacturers developing or manufacturing deferasirox formulations should review the patent claims to assess freedom-to-operate implications. Drug product developers and generic manufacturers may find this relevant for formulation strategies targeting improved patient compliance through self-dispersing delivery systems.